Dr Jeffrey Lancet Discusses the Evolving Therapy Landscape of AML
May 4th 2023Jeffrey E. Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center, gave insight on the evolving treatment landscape of acute myeloid leukemia (AML) and the potential of immunotherapy and targeted therapies going forward.
Watch
For Treatment Resistance in NSCLC, Repeat Biomarker Testing Is Key, Says Dr Mark Socinski
May 4th 2023Mark A. Socinski, MD, executive director of AdventHealth Cancer Institute, gave insight into treatment resistance and the importance of repeat biomarker testing at the time of disease progression in non–small cell lung cancer (NSCLC).
Watch
Julie Reed: The Status Quo for Biosimilars Needs to Change to Maintain the Industry
May 4th 2023The 2023 Asembia Specialty Pharmacy Summit featured Juliana (Julie) Reed, executive director of the Biosimilars Forum, who spoke on the challenges still facing the biosimilars industry and how they may impact the success of adalimumab biosimilars in the United States.
Read More
The DEA desires to extend its COVID-19 prescription flexibilities; the Biden administration warns Americans to avoid medical credit cards; more US women are avoiding unwanted or ill-timed pregnancies, but a growing share of women over 35 say their pregnancies are coming later than desired.
Read More
Patients With Prostate Cancer Most Concerned With ADT Cost, Delivery Method
May 4th 2023A cross-sectional survey of patient preferences found that the out-of-pocket cost of treatment was the most impactful attribute for patients when choosing an androgen deprivation therapy (ADTs) for their prostate cancer.
Read More
Iptacopan Meets Primary End Point of APPOINT-PNH Trial in Paroxysmal Nocturnal Hemoglobinuria
May 4th 2023Iptacopan elicited improved hemoglobin levels measuring at least 2 g/dL higher vs baseline, leading to transfusion independence after 24 weeks in approximately 92.2% of patients with complement inhibitor–naïve paroxysmal nocturnal hemoglobinuria.
Read More
Dr Stephen Schleicher: Rural Patient Care Access Is a Top Priority for Community Oncology
May 4th 2023Stephen M. Schleicher, MD, MBA, Tennessee Oncology, co-authored a recent paper on the complexities of the rural cancer experience; the principal conclusion was potential for a streamlined care process to optimize care efficiencies and access, thereby improving patient outcomes.
Watch
NHIA's Connie Sullivan Discusses the Benefits and Patient Satisfaction of Home Infusion
May 3rd 2023Connie Sullivan, president and CEO of the National Home Infusion Association (NHIA), discusses why at-home infusion is beneficial to patients and why so many patients reported feeling satisfied with home administration.
Watch
AI Cannot Assist in Prepping for Ophthalmology Board Certification Exams, Study Finds
May 3rd 2023When presented with a set of multiple choice questions used to help trainees practice for the ophthalmology board certification exams, the artificial intelligence (AI) chatbot ChatGPT was able to answer only half correctly.
Read More
What We’re Reading: HPV Vaccine Protects for 3 Years; Alzheimer Drug Results; NY Birth Control Law
May 3rd 2023One dose of human papillomavirus vaccine (HPV) vaccine can prevent infection for at least 3 years, and maybe even longer; Eli Lilly plans to seek FDA approval for Alzheimer drug that slows decline; New York governor signed a bill expanding contraceptive access in the state next year.
Read More
Digital Tools May Help Improve Patient Experience, but Human Connection Is Still Needed
May 3rd 2023Although digital tools can be immensely helpful for creating a personalized, convenient interaction between patients and the health care system, they should not be the end-all be-all method to improve the patient experience, according to a panel discussion at the 2023 Asembia Specialty Pharmacy Summit.
Read More
Survey Shows Payers More Likely to Prefer Multiple Biosimilars for the Same Reference Product
May 2nd 2023In a panel at the 2023 Asembia Specialty Pharmacy Summit, speakers presented on the payer perspective regarding biosimilars, including that they feel comfortable preferring multiple biosimilars for the same reference product and are looking for interchangeability designations.
Read More